Overview

It has been almost 20 years since the discovery by Kohler and Milstein of the technology to produce monoclonal antibodies (MAbs), a discovery that promised revolutionary changes in research, clinical diagnosis and human therapy. From today's perspective, it is fair to conclude that this promise has been realized in two areas of the three. As research tools, MAbs have been invaluable: their ability to selectively bind and localize specific antigens, detect and identify new ligands and their receptors, and agonize and/or antagonize specific molecular interactions continues to provide a useful and enabling technology to basic research endeavors. Similarly, MAbs have demonstrated enormous practical impact as diagnostic tools. Recent advances in clinical diagnostic medicine continue to rely heavily on the use of MAb-based reagents for detecting and localizing antigens of clinical import. In contrast, however, MAbs have not proven to have major impact on human disease therapy. With the single exception of an immunosup­ pressive MAb against the T-cell antigen, CD3, MAbs have as yet found few meaningful applications as therapeutic agents. During the 1980s, a set of technologies to clone, modify and express genes encoding MAbs was developed. These breakthroughs permitted MAbs to be genetically engineered which consequently gave them the potential to greatly enhance their therapeutic utility as well as significantly expand their research and diagnostic applications. New MAbs, fragments of MAbs, bispecific MAbs, single-chain MAbs, and fusions of MAbs with other gene products became available for study.

Full Product Details

Author:   Martin Rosenberg ,  R. Balint ,  Gordon P. Moore ,  C.F. Barbas
Publisher:   Springer-Verlag Berlin and Heidelberg GmbH & Co. KG
Imprint:   Springer-Verlag Berlin and Heidelberg GmbH & Co. K
Edition:   Softcover reprint of the original 1st ed. 1994
Volume:   113
Dimensions:   Width: 15.50cm , Height: 2.20cm , Length: 23.50cm
Weight:   0.657kg
ISBN:  

9783642784347

ISBN 10:   3642784348
Pages:   406
Publication Date:   22 January 2012
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

Section I: Human Monoclonal Antibodies.- 1 Human Monoclonal Antibody Technology.- 2 Recombinant Therapeutic Human Monoclonal Antibodies.- 3 Transgenic Approaches to Human Monoclonal Antibodies.- Section II: Genetically Engineered Monoclonal Antibodies.- 4 Humanization of Monoclonal Antibodies.- 5 Applications for Escherichia coli-Derived Humanized Fab’ Fragments: Efficient Construction of Bispecific Antibodies.- Section III: MAb Conjugates and Fusions.- 6 Immunotoxins.- 7 Antibody-Enzyme Fusion Proteins and Bispecific Antibodies.- 8 Three Generations of Recombinant CD4 Molecules as Anti-HIV Reagents.- Section IV: Combinatorial Libraries.- 9 Chemical and Biological Approaches to Catalytic Antibodies.- 10 The Combinatorial Approach to Human Antibodies.- Section V: Expression of MAbs/MAb Fragments.- 11 Antibodies from Escherichia coli.- 12 Structure, Function and Uses of Antibodies from Transgenic Plants and Animals.- 13 Some Aspects of Monoclonal Antibody Production.- Section VI: Medical Applications.- 14 Prospects for Cancer Imaging and Therapy with Radioimmunoconjugates.- 15 Clinical Experience with Murine, Human and Genetically Engineered Monoclonal Antibodies.- 16 Anti-idiotypic Monoclonal Antibodies: Novel Approach to Immunotherapy.

Reviews

Author Information

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions